- Home
- CGTL vs STRO Comparison
CGTL vs STRO Comparison
Compare CGTL & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTL
- STRO
- Stock Information
- Founded
- CGTL 2016
- STRO 2003
- Country
- CGTL Hong Kong
- STRO United States
- Employees
- CGTL N/A
- STRO N/A
- Industry
- CGTL
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGTL
- STRO Health Care
- Exchange
- CGTL NYSE
- STRO Nasdaq
- Market Cap
- CGTL 152.2M
- STRO 147.6M
- IPO Year
- CGTL 2024
- STRO 2018
- Fundamental
- Price
- CGTL $5.15
- STRO $1.77
- Analyst Decision
- CGTL
- STRO Strong Buy
- Analyst Count
- CGTL 0
- STRO 7
- Target Price
- CGTL N/A
- STRO $12.14
- AVG Volume (30 Days)
- CGTL 13.0K
- STRO 950.7K
- Earning Date
- CGTL 03-04-2025
- STRO 03-24-2025
- Dividend Yield
- CGTL N/A
- STRO N/A
- EPS Growth
- CGTL 35.72
- STRO N/A
- EPS
- CGTL 0.21
- STRO N/A
- Revenue
- CGTL $35,611,761.00
- STRO $160,955,000.00
- Revenue This Year
- CGTL N/A
- STRO N/A
- Revenue Next Year
- CGTL N/A
- STRO N/A
- P/E Ratio
- CGTL $24.05
- STRO N/A
- Revenue Growth
- CGTL N/A
- STRO 230.90
- 52 Week Low
- CGTL $3.37
- STRO $1.51
- 52 Week High
- CGTL $10.59
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- CGTL N/A
- STRO 42.89
- Support Level
- CGTL N/A
- STRO $1.76
- Resistance Level
- CGTL N/A
- STRO $1.95
- Average True Range (ATR)
- CGTL 0.00
- STRO 0.13
- MACD
- CGTL 0.00
- STRO 0.00
- Stochastic Oscillator
- CGTL 0.00
- STRO 41.94
About CGTL CREATIVE GLOBAL TECHNOLOGY HOLDINGS LIMITED
Creative Global Technology Holdings Ltd Conducts its business through its subsidiary, which is a Hong Kong-based company sourcing and reselling recycled consumer electronic devices, currently mostly smartphones, tablets, and laptops.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.